Connect with us

Biotech

Frontwave Opens its Capital to Femu Ventures to Initiate Human Trials

The clinical trials will initially be carried out at the Vall d’Hebron Hospital in Barcelona and will be coordinated by the Catalan hospital’s Research Institute. Subsequently, the company aims to move the trials to a “multicenter” phase. In addition, the company is preparing another financing round of $1.76 million (€1.5 million) at the end of 2022.

Published

on

Frontwave obtains resources to further develop. The investment fund Femu Ventures has entered the Spanish company’s capital, sources close to the company have confirmed. This company commercializes a 3D ultrasound supercomputing software, UBIware, and aims to more efficiently identify breast cancer cases.

Femu has been one of the main investors in a financing round that has raised $880,000 (€750,000). In addition to the fund, Frontwave has had the support of other private investors, different business angels, and the company’s own team.

The objective of this round, which has been closed during the last few days, is to finance the first human trials and to expand the current staff of fifteen workers, according to Frontwave’s financial sources.

Read more on the subject and find the latest business news in the world with our companion app Born2Invest.

Frontwave expects to open another financing round, this time for more than $1.76 million (€1.5 million), by the end of 2022

The clinical trials will initially be carried out at the Vall d’Hebron Hospital in Barcelona and will be coordinated by the Catalan hospital’s Research Institute. Subsequently, the company aims to move the trials to a “multicenter” phase.

In addition, the company is preparing another financing round of $1.76 million (€1.5 million) at the end of 2022. Subsequently, once the product is on the market in 2023, the company plans to expand UBIware to Europe, the United States, and China.

The Asian giant is shaping up to be a highly attractive market for Frontwave. Firstly, because of the low maturity of breast cancer screening systems in the country and, in addition, because of the higher prevalence of dense breasts among the population.

SEE ALSO  ASIC launches new initiative aimed to help Aussies with money

The company expects to have a turnover of $235,000 (€200,000) in 2023, once the product is certified by clinical trials

The company, which was created as a spin-off of the BSC and Imperial College London, assures that the potential differential of Frontwave is the higher quality of the images thanks to its software system, which compiles the data from the ultrasound devices. This higher quality would allow more accurate diagnosis of breast cancer diagnostic tests, especially in cases of women with dense breasts.

Once the product is certified by clinical trials, the company expects to have a turnover of $235,000 (€200,000 by 2023 and, in addition, to be producing 3D images at a maximum cost of one hundred dollars by 2025.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.